Filter By Category
Archives
Share on -
ABICIPAR PEGOL
Generic Name: ABICIPAR PEGOL
ABSTRACT -
abicipar pegol is a protein- or peptide-based API listed in the supplied A-series master. Exact sequence, post-translational modifications, pharmacology, and indication must be verified from the applicable product dossier or protocol.
DOSAGE –
Use the current locally approved prescribing information where a product is authorized. For investigational products, dose, route, schedule, premedication, and dose modifications must come only from the applicable clinical-trial protocol. No dose should be selected from this summary.
SIDE EFFECTS –
- Infusion or injection reactions
- Fever or chills
- Headache
- Rash
- Nausea
- Development of anti-drug antibodies or loss of response
ALLRGIC REACTIONS–
(These symptoms may indicate a serious allergic or infusion reaction and require medical attention.)
- Hives or a rapidly spreading rash
- Swelling of the face, lips, tongue, or throat
- Wheezing, breathing difficulty, or sudden dizziness
- Severe blistering, mucosal lesions, or anaphylaxis
DRUG INTERACTIONS -
- Other biologics may increase hypersensitivity or immune effects
- Immunosuppressive therapy may alter immunogenicity
- Combination therapy should follow the authorized protocol
PRECAUTIONS –
- Monitor during administration
- Assess for antibodies or reduced response when clinically relevant
- Verify storage, preparation, and route before use
WARNINGS –
Severe hypersensitivity, anaphylaxis, or target-related systemic effects can occur
Share on -
. Developed by